Cisco Systems Inc vs Eli Lilly And Co — how do they compare? Cisco Systems Inc trades at $115.5 (market cap $462.82B), while Eli Lilly And Co trades at $1,166.49 (market cap $1.06T). The key difference: Eli Lilly And Co is far larger — about 2.3× Cisco Systems Inc's market cap, and Cisco Systems Inc pays the higher dividend (1.43%). Which is the better fit depends on your goals — on Pluang, investors hold Cisco Systems Inc for 86 Days and Eli Lilly And Co for 93 Days on average.
| CSCO | LLY | |
|---|---|---|
Market Cap | $462.82B | $1.06T |
Volume | 17,198,164 | 2,297,239 |
Sector | Technology | Health |
52-Week High | $130.00 | $1.28K |
52-Week Low | $67.46 | $799.57 |
Typical Hold Time | 86 Days | 93 Days |
Enterprise Value | $476.44B | $1.11T |
Dividend Yield | 1.43% | 0.58% |
Signals from Pluang's Aura AI — not financial advice
Cisco Systems (CSCO) trades at $114.89, down 2.59% on the day, as the stock consolidates near recent highs. The company demonstrates strong fundamentals with Q2 2026 EPS beating expectations at $1.22 versus $1.17, continuing a trend of earnings outperformance. Technical indicators show a bullish moving average trend while oscillators suggest potential near-term consolidation. Recent news highlights Cisco's AI-driven networking momentum with Splunk integration and partnerships with NVIDIA, supporting multi-year growth prospects in AI infrastructure.
Cisco presents a compelling investment case with robust profitability metrics (64.52% gross margin, 27.32% ROE) and analyst consensus pointing to 13% upside to the $129.77 price target. Key risks include competitive pressure in AI security from Datadog and CrowdStrike, and the stock's elevated valuation multiples (P/E 35.25, P/S 7.39) that require continued execution. The company's strong cash flow generation and dividend payments provide shareholder value support.
Eli Lilly (LLY) trades at $1,169.93, up 1.07% on the day, with a bullish technical signal and strong fundamental momentum. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $8.38 exceeding the $6.40 estimate. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Positive news flow highlights promising pipeline updates in weight-loss and diabetes drugs, reinforcing growth prospects.
Outlook remains favorable given dominant market position and innovation pipeline, though high valuation multiples pose a risk. Analyst consensus is strongly bullish with a $1,340 price target. Key risks include competitive pressures and execution challenges in scaling production to meet demand for blockbuster therapies.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Cisco Systems, Inc. provides information technology and networking services. The Company offers enterprise network security, software development, data collaboration, cloud computing, and other related services. Cisco Systems serves customers in the United States.
Read more on CSCO →Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →